Navigation Links
Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
Date:8/24/2009

CAMBRIDGE, Mass., Aug 24 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces today that it has entered into a research-based collaboration with Santaris Pharma A/S, a leading player in RNA-based therapeutics, to develop its proprietary Locked Nucleic Acid (LNA) technology in a range of rare diseases, thereby enabling Shire to build on its already strong competitive position for its Human Genetic Therapies (HGT) business. LNA technology has the benefit of a very quick validated target to proof of concept turnaround, thereby increasing the speed and lowering the cost of development.

Currently, Shire HGT has a unique and successful platform producing human cell derived enzyme replacement therapies (ERTs) for a wide range of rare human genetic disorders.

Sylvie Gregoire, President of Shire HGT, comments, "With this novel platform technology Shire has the potential to move into a wider range of genetic orphan diseases. We will look to develop treatments for people with a variety of rare life-altering and life-threatening conditions that to date, could not be effectively addressed by enzyme replacement therapy."

As part of the joint research project Santaris Pharma A/S will design, develop and deliver pre-clinical LNA oligonucleotides specific for the selected Shire targets, and Shire will have the right to further develop and commercialize these candidate compounds on a worldwide basis.

About Locked Nucleic Acid (LNA) Drug Platform

The Locked Nucleic Acid (LNA) Drug Platform developed by Santaris Pharma A/S creates synthetic chemical versions called LNAs of the normal nucleic acid building blocks of ribonucleic acids (RNA). These LNAs improve the drug-like qua
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business
2. Shires ELAPRASE(R) (idursulfase) Approved in Japan for the Treatment of Hunter Syndrome
3. Shire Divests Non-Core Product Portfolio to Almirall
4. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
5. David Mott Appointed Non Executive Director at Shire
6. Shire plc: Board Changes
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
10. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
11. Shire Engages Palio
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... , ... CSM, a leading clinical trial supply company, today announced that Michael ... extensive background in financial management and accounting, bringing over 20 years of experience in ... will oversee all financial areas of the company to both strengthen CSM’s financial strategy ...
(Date:7/6/2015)... ... July 06, 2015 , ... A study ... insights into how virulent fungi adapt through genetic modifications to fight back against ... leaves them temporarily weakened. These insights may provide clues to new ways to ...
(Date:7/6/2015)... Wellesley, Mass. (PRWEB) , ... July 06, 2015 ... ... development of simpler and cheaper molecular diagnostic tests are key drivers of the ... projected growth of personalized medicine and the introduction of new companion diagnostic tests ...
(Date:7/6/2015)... -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE MKT: IMUC) today ... Clinical (Novella), to conduct the phase 3 registration ... Novella is a full-service, global clinical research organization (CRO) ... companies. The ICT-107 phase 3 trial will include approximately ... and Canada , and ...
Breaking Biology Technology:CSM Appoints Michael Morse as Vice President of Finance 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 2Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 3Worcester Polytechnic Institute Co-directs Study That Provides New Insights into the Genetics of Drug-Resistant Fungal Infections 4Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 2Demand for Personalized Medicine, Innovative Molecular Diagnostic Tests Spurring Big Growth, According to BCC Research 3ImmunoCellular Therapeutics Establishes Agreement with Novella Clinical to Conduct ICT-107 Phase 3 Registration Trial in Glioblastoma 2
... Catholic Health Initiatives, (CHI) Institute for Research and ... have announced a joint strategic partnership to focus ... community hospitals across their system. ... clinical R&D and molecular diagnostics laboratory that supports ...
... (Nasdaq: LIFE ), a provider of innovative ... bioenergy crop company, today announced they have completed sequencing the ... SOLiD™ 4.0 System by Life Technologies. The sequence ... crop and advances its development as a high yielding, low-cost ...
... a global leader in material science and high-performance polymer ... 6 languages: English, Chinese, French, German, Japanese, and Spanish. ... Account Managers and modified customer support hours to better ... for download at http://www.zeusinc.com . ...
Cached Biology Technology:BioFortis and Catholic Health Initiatives' Center for Translational Research Announce Biorepository Information Technology Strategic Partnership to Drive Progress in Personalized Medicine 2BioFortis and Catholic Health Initiatives' Center for Translational Research Announce Biorepository Information Technology Strategic Partnership to Drive Progress in Personalized Medicine 3Life Technologies and SG Biofuels Complete Sequence of Jatropha Genome 2Life Technologies and SG Biofuels Complete Sequence of Jatropha Genome 3Life Technologies and SG Biofuels Complete Sequence of Jatropha Genome 4Zeus Catalog Available in Six Languages 2
(Date:6/18/2015)... , June 18, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market announces that its ... segment on "Money on the Mark", scheduled to air on ... June 20 th . The broadcast ... from 7:00 to 8:00pm EST. NXT-ID, Inc.,s CEO Gino ...
(Date:6/17/2015)... Germany , June 17, 2015 ... today launched new Investigator ® STR assay kits for ... the United States . The new genetic fingerprint kits ... markers (short tandem repeats or STRs) for DNA matching. They ... quality of DNA in each sample, a novel QIAGEN technology ...
(Date:6/17/2015)... BEACH GARDENS, Fla. , June 17, 2015 ... management solutions, today announced that its U.are.U ® ... Togo,s Eateries, Inc., a ... fast casual sandwich chain, to increase security, improve ... Crossmatch fingerprint readers enable instant, non-repudiable identity confirmation ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3
... The National Institute of Neurological Disorders and Stroke (NINDS), ... a three-year, $900,000 grant to the Center for Biomedical ... The grant will fund the center,s biomarker research in ... detect changes in brain function and biochemistry. Led ...
... February 14, 2013 The 18th century natural philosopher ... as a consequence of the cumulative effort, across generations, ... view of evolution was largely abandoned with the advent ... most important traits and many medical illnesses across generations. ...
... assortment of amphibian species living in a pond, the more ... a parasitic infection that can cause severe deformities, including the ... the University of Colorado Boulder. The findings, published ... idea that greater biodiversity in larger-scale ecosystems, such as forests ...
Cached Biology News:NIH funds research to identify Parkinson's biomarkers 2NIH funds research to identify Parkinson's biomarkers 3Life experiences put their stamp on the next generation: New insights from epigenetics 2CU-Boulder amphibian study shows how biodiversity can protect against disease 2CU-Boulder amphibian study shows how biodiversity can protect against disease 3CU-Boulder amphibian study shows how biodiversity can protect against disease 4
Homo sapiens postsynaptic protein CRIPT Antigen: Recombinant Protein...
... quadrupole 1200L sets the new standard ... - incorporating the latest technologies and ... chromatography analytical needs. The Atmospheric ... Transmission Quadrupole Analyzer provide superior selectivity ...
Human Legumain Affinity Purified Polyclonal Ab...
Mouse Endoglin/CD105 Fluorescein MAb (Clone 209701)...
Biology Products: